ASCO 2022 Conference Coverage


 

ASCO 2022 Neoadjuvant HER2-Targeted Therapy +/- Immunotherapy With Pembrolizumab: An Open Label Randomized Phase 2 Trial

82 views
June 16, 2022
0 Comments
Login to view comments. Click here to Login
Breast